Background
Methods
Patients
RNA-seq analysis
Differential expression analysis
Self-organizing map analysis
Pathway analysis
Results
Study workflow
Differential expression analysis
SOM clustering analysis
Condition | Expression pattern | Criteria |
---|---|---|
Ischemia effect | Upregulated | \( {\left\{\left[{\mathit{\log}}_2\left(\overline{I}/\overline{P}\right)\right]\right\}}_{module_i}\ge 1\ AND\ {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{P}\right)\right]\right\}}_{module_i}\ge 1 \) |
Downregulated | \( {\left\{\left[{\mathit{\log}}_2\left(\overline{I}/\overline{P}\right)\right]\right\}}_{module_i}\le 1\ AND\ {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{P}\right)\right]\right\}}_{module_i}\le 1 \) | |
Reperfusion effect | Upregulated | \( {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{I}\right)\right]\right\}}_{module_i}\ge 1\ AND\ {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{P}\right)\right]\right\}}_{module_i}\ge 1 \) |
Downregulated | \( {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{I}\right)\right]\right\}}_{module_i}\le 1\ AND\ {\left\{\left[{\mathit{\log}}_2\left(\overline{R}/\overline{P}\right)\right]\right\}}_{module_i}\le 1 \) |
Clusters | Module number | Number of genes | Total number of genes | |
---|---|---|---|---|
Ischemia effect | Cluster 1 (Upregulated) | 42, 44, 45, 46, 48, 49 | 633 | 3035 |
Cluster 2 (Downregulated) | 1, 8, 11, 17, 19 | 2402 | ||
Reperfusion effect | Cluster 3 (Upregulated) | 36, 43 | 227 | 1917 |
Cluster 4 (Downregulated) | 15, 16, 23 | 1690 |
Ingenuity canonical pathway | BHb p-value | Genes |
---|---|---|
Adipogenesis pathway | 0.0022 | BMP4, BMPR1A, CLOCK, CTBP2, CTNNB1, EGR2, ERCC3,FGF1,FGFR2,FOXC2,FZD2,GTF2H1,GTF2H2,HAT1,HDAC1,HDAC4,HDAC6,HDAC7,HIF1A,KLF5,NFATC4,NR1D2,NR2F2,PPIP5K1,SAP30,SETDB1,SIRT1,SREBF1,TBL1XR1,TGFB1,TNF,TNFRSF1A,TP53,TXNIP,XBP1 |
Aryl hydrocarbon receptor signaling | 0.0044 | ALDH1A3,ALDH1L1,ALDH3A2,ALDH4A1,ALDH6A1,ALDH7A1,CDKN1A,FAS,GSTA1,GSTA2,GSTK1,GSTP1,HSPB2,HSPB7,IL6,MAPK3,MAPK8,MCM7,MDM2,MGST1,MGST3,NCOA7,NCOR2,NFIX,NQO2,NR2F1,RARB,RBL2,SMARCA4,TFF1,TGFB1,TGFB2,TNF,TP53 |
PXR/RXR activation | 0.0044 | ABCC2,ABCC3,AKT2,ALDH3A2,CES2,CES3,CYP3A5,CYP3A7,G6PC,GSTA1,GSTA2,HNF4A,IL6,NCOA1,NR1I3,PCK2,PRKACB,TNF,UGT1A1,UGT1A7 |
Protein ubiquitination pathway | 0.0044 | ANAPC2,ANAPC4,ANAPC5,BIRC2,BIRC6,CRYAA/CRYAA2,CRYAB,DNAJC10,DNAJC12,DNAJC22,DNAJC30,DNAJC7,HLA-A,HLA-B,HLA-C,HLA-E,HSPA2,HSPA4,HSPB2,HSPB7,HSPD1,MDM2,PSMA1,PSMA3,PSMB3,PSMB8,PSMC3,PSMD2,PSME2,SKP1,SKP2,SMURF2,TAP1,UBB,UBE2A,UBE2E1,UBE2E3,UBE2F,UBE2J2,UBE2Q2,UBR2,UCHL1,USP15,USP19,USP2,USP21,USP24,USP28,USP33,USP36,USP4,USP48,USP53,USP54,USP8 |
Xenobiotic metabolism signaling | 0.0044 | ABCC2,ABCC3,ALDH1A3,ALDH1L1,ALDH3A2,ALDH4A1,ALDH6A1,ALDH7A1,ANKRA2,CAMK1G,CAT,CES1,CES2,CES3,CHST1,CHST15,CITED2,CYP3A5,CYP3A7,DNAJC7,EIF2AK3,FMO1,FMO5,GSTA1,GSTA2,GSTK1,GSTP1,HDAC4,HS3ST6,IL6,MAF,MAOA,MAPK14,MAPK3,MAPK8,MAPK9,MGST1,MGST3,NCOA1,NCOR2,NDST2,NQO2,NR1I3,PIK3R4,PPP2R2B,PRKCB,PRKD3,PTPA,RAF1,SULT1C2,SULT2B1,TNF,UGT1A1,UGT1A6,UGT1A7,UGT2B7,UGT8,UST |
Apelin adipocyte signaling pathway | 0.0044 | ADCY3,ADCY5,ADCY6,ADCY7,CAT,CYBB,GNAI2,GPX3,GPX8,GSTA1,GSTK1,GSTP1,HIF1A,MAPK14,MAPK15,MAPK3,MAPK8,MAPK9,MGST1,MGST3,NOX4,PRKAB1,PRKACB |
Death receptor signaling | 0.0085 | ACTB,BIRC2,CASP2,CASP6,CASP7,FAS,HSPB2,HSPB7,IKBKG,LIMK1,MAPK8,PARP11,PARP12,PARP14,PARP6,PARP8,RIPK1,SPTAN1,TANK,TNF,TNFRSF10B,TNFRSF1A,TNFRSF25,TNFSF10 |
LPS/IL-1-mediated inhibition of RXR function | 0.0135 | ABCC2,ABCC3,ABCG1,ACOX2,ACSL4,ALDH1A3,ALDH1L1,ALDH3A2,ALDH4A1,ALDH6A1,ALDH7A1,APOE,CAT,CES2,CHST1,CHST15,CPT1B,CYP3A5,CYP3A7,CYP4A11,FABP1,FMO1,FMO5,GSTA1,GSTA2,GSTK1,GSTP1,HMGCS1,HS3ST6,IL1RL1,MAOA,MAPK8,MAPK9,MGST1,MGST3,NCOA1,NDST2,NR1I3,SLC27A2,SREBF1,SULT1C2,SULT2B1,TNF,TNFRSF1A,UST |
Hepatic fibrosis/hepatic stellate cell activation | 0.0135 | AGTR1,CCL5,COL12A1,COL15A1,COL16A1,COL18A1,COL1A2,COL3A1,COL4A3,COL4A5,COL5A2,COL5A3,COL6A1,COL6A2,COL6A3,COL7A1,CSF1,ECE1,EDNRB,FAS,FGF1,FGFR2,FN1,IGF2,IL1RL1,IL6,IL6R,KLF6,LEPR,MYL6B,PDGFA,PDGFRB,SMAD4,TGFA,TGFB1,TGFB2,TIMP1,TNF,TNFRSF1A |
TR/RXR activation | 0.0135 | ACACA,AKR1C1/AKR1C2,AKT2,BCL3,COL6A3,DIO1,G6PC,GPS2,HIF1A,LDLR,MDM2,NCOA1,NCOR2,PCK1,PIK3R4,SLC16A2,SLC16A3,SREBF1,SREBF2,TBL1XR1,THRA,UCP2 |
Ingenuity canonical pathway | BHb p-value | Genes |
---|---|---|
Semaphorin signaling in neurons | 0.0003 | CFL1,FYN,LIMK2,MET,PAK4,PLXNB1,PTK2,RAC1,RHOBTB1,RHOC,RHOT2,RHOV,RND1,RND3,ROCK1,ROCK2,SEMA4D |
mTOR signaling | 0.0003 | AKT1,AKT2,AKT3,EIF3B,EIF3D,EIF3E,EIF3F,EIF3H,EIF3J,EIF4A2,FKBP1A,IRS1,KRAS,MAPKAP1,PGF,PLD2,PPP2R2B,PPP2R5C,PRKAG1,PRR5,RAC1,RHOBTB1,RHOC,RHOT2,RHOV,RND1,RND3,RPS10,RPS13,RPS18,RPS2,RPS20,RPS24,RPS5,RPS6KA3,RPS8,RPSA |
eIF2 signaling | 0.0003 | ACTB,AKT1,AKT2,AKT3,CDK11A,EIF2B1,EIF2B4,EIF3B,EIF3D,EIF3E,EIF3F,EIF3H,EIF3J,EIF4A2,HNRNPA1,KRAS,MYCN,PPP1CA,RPL12,RPL13A,RPL17,RPL24,RPL30,RPL31,RPL35A,RPL7,RPL8,RPS10,RPS13,RPS18,RPS2,RPS20,RPS24,RPS5,RPS8,RPSA,SREBF1,TRIB3 |
Superpathway of cholesterol biosynthesis | 0.0023 | ACAT1,HADHB,HMGCR,HSD17B7,LBR,MVD,MVK,SC5D,SQLE,TM7SF2 |
Integrin signaling | 0.0023 | ACTB,AKT1,AKT2,AKT3,ARF1,ARF4,ARPC2,ARPC3,ARPC5,ARPC5L,BCAR1,BCAR3,CAPN1,CAPN10,FYN,GRB7,ILK,KRAS,NEDD9,PAK4,PTK2,RAC1,RHOBTB1,RHOC,RHOT2,RHOV,RND1,RND3,ROCK1,TLN1,TNK2,TSPAN1,TSPAN4,ZYX |
Ephrin receptor signaling | 0.0023 | ACP1,AKT1,AKT2,AKT3,ARHGEF15,ARPC2,ARPC3,ARPC5,ARPC5L,BCAR1,CFL1,CREBBP,EFNA1,FGF1,FYN,GNAS,GRINA,KRAS,LIMK2,PAK4,PDGFA,PGF,PTK2,PTPN13,RAC1,ROCK1,ROCK2,SDC2,SH2D3C,STAT3 |
Apelin muscle signaling pathway | 0.0023 | AKT1,AKT2,AKT3,APLNR,GNAS,NOS3,NRF1,PRKAG1 |
Antigen presentation pathway | 0.0055 | CALR,CD74,HLA-A,HLA-DMB,HLA-DOA,HLA-DQB2,HLA-F,MR1,NLRC5,TAP1,TAPBP |
Shingosine-1-phosphate signaling | 0.0071 | ADCY3,ADCY4,AKT1,AKT2,AKT3,ASAH2B,CASP9,PDGFA,PDGFRB,PLCB1,PLCB4,PLCD1,PTK2,RAC1,RHOBTB1,RHOC,RHOT2,RHOV,RND1,RND3,S1PR1 |
Regulation of actin-based motility by Rho | 0.0072 | ACTB,ARHGDIA,ARPC2,ARPC3,ARPC5,ARPC5L,CFL1,PAK4,PIP5K1A,PIP5K1B,RAC1,RHOBTB1,RHOC,RHOT2,RHOV,RND1,RND3,ROCK1 |